Why the study?
Does restoration of blood flow via pharmacomechanical catheter-directed thrombolysis within a restricted intermediate timeframe (4-8 days after symptom onset) improve quality of life and reduce post-thrombotic syndrome severity compared to anticoagulation alone in patients with acute proximal DVT?
Does restoration of blood flow via pharmacomechanical catheter-directed thrombolysis within a restricted intermediate timeframe (4-8 days after symptom onset) improve quality of life and reduce post-thrombotic syndrome severity compared to anticoagulation alone in patients with acute proximal DVT?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Overall, these animal data suggest RBF in acute, proximal DVT, whether achieved by mechanical or pharmacomechanical means, is more likely to occur if the intervention occurs early, and early RBF by any means reduces long-term molecular and cellular consequences of DVT. In ATTRACT, subjects randomized early after symptom onset did not benefit from PCDT, and this may indicate that therapeutic anticoagulation alone is effective for fresh thrombus, highlighting the importance of rapidly achieved anticoagulation. In contrast, late intervention may occur beyond a reversible period of DVT sequelae. Clinicians may need to target individuals who have failed early medical therapy but before the long-term pathophysiological consequences of DVT are triggered.”
Translational and post-hoc clinical evidence indicates that blood flow restoration in acute DVT has a restricted therapeutic time window (days 4-8 from symptom onset in humans) during which catheter-directed thrombolysis maximally improves quality of life and reduces post-thrombotic syndrome severity.
Background: Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution. Methods: First, experimental stasis DVT was generated in C57/BL6 mice (n=291) by inferior vena cava ligation. To promote RBF, mice underwent mechanical deligation with or without intravenous recombinant tissue plasminogen activator administered 2 days after deligation. RBF was assessed over time by ultrasonography and intravital microscopy. Resected thrombosed inferior vena cava specimens underwent thrombus and vein wall histological and gene expression assays. Next, in a clinical study, we conducted a post hoc analysis of the ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) pharmacomechanical catheter-directed thrombolysis (PCDT) trial (NCT00790335) to assess the effects of PCDT on Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores for specific symptom-onset-to-randomization timeframes. Results: Mice that developed RBF by day 4, but not later, exhibited reduced day 8 thrombus burden parameters and reduced day 8 vein wall fibrosis and inflammation, compared with controls. In mice without RBF, recombinant tissue plasminogen activator administered at day 4, but not later, reduced day 8 thrombus burden and vein wall fibrosis. It is notable that, in mice already exhibiting RBF by day 4, recombinant tissue plasminogen activator administration did not further reduce thrombus burden or vein wall fibrosis. In the ATTRACT trial, patients receiving PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days demonstrated maximal benefits in Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores (between-group difference=8.41 and 1.68, respectively, P <0.001 versus patients not receiving PCDT). PCDT did not improve postthrombotic syndrome scores for patients having a symptom-onset-to-randomization time of <4 days or >8 days. Conclusions: Taken together, these data illustrate that, within a restricted therapeutic window, RBF improves DVT resolution, and PCDT may improve clinical outcomes. Further studies are warranted to examine the value of time-restricted RBF strategies to reduce postthrombotic syndrome in patients with DVT.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Acute proximal deep vein thrombosis (DVT) (n=691). Pharmacomechanical catheter-directed thrombolysis (PCDT) and mechanical deligation with or without recombinant tissue plasminogen activator (rtPA) vs. Anticoagulation alone (human cohort); sham deligation or saline control (murine model) was evaluated on VEINES-QoL score in the intermediate symptom-onset-to-randomization timeframe (4 to 8 days) (MD 8.41, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: